Bachem Holding AG/Fr. BANB
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Bachem Holding AG
Bachem Holding AG is a Swiss company specializing in the biotechnology and pharmaceutical industries. It focuses on the development and production of peptides and oligonucleotides for the pharmaceutical and biotech sectors. Its offerings include active pharmaceutical ingredients (APIs) and customized synthesis services. Founded in 1971, Bachem's headquarters is located in Bubendorf, Switzerland, with additional facilities in the United States, Europe, and Asia. The company is known for its extensive expertise in peptide chemistry and its strategic focus on innovation and quality in manufacturing, contributing to its competitive position in the global pharmaceuticals market.
- Ticker
- Fr. BANB
- Sector
- Health
- Primary listing
- XSWX
- Employees
- 2,725
- Headquarters
- Bubendorf, Switzerland
- Website
- www.bachem.com
BANB Metrics
BasicAdvanced
CHF 6.3B
42.17
CHF 1.98
0.79
CHF 0.90
0.54%
Price and volume
Market cap
CHF 6.3B
Beta
0.79
52-week high
CHF 86.00
52-week low
CHF 48.52
Average daily volume
86K
Dividend rate
CHF 0.90
Financial strength
Current ratio
1.604
Quick ratio
0.456
Long term debt to equity
0
Total debt to equity
0.144
Dividend payout ratio (TTM)
45.30%
Interest coverage (TTM)
149.30%
Profitability
EBITDA (TTM)
210.448
Gross margin (TTM)
27.00%
Net profit margin (TTM)
21.02%
Operating margin (TTM)
21.81%
Effective tax rate (TTM)
5.05%
Revenue per employee (TTM)
CHF 260,000
Management effectiveness
Return on assets (TTM)
4.54%
Return on equity (TTM)
10.63%
Valuation
Price to earnings (TTM)
42.166
Price to revenue (TTM)
8.865
Price to book
4.37
Price to tangible book (TTM)
4.46
Price to free cash flow (TTM)
-107.864
Free cash flow yield (TTM)
-0.93%
Free cash flow per share (TTM)
-0.776
Dividend yield (TTM)
1.08%
Forward dividend yield
0.54%
Growth
Revenue change (TTM)
4.51%
Earnings per share change (TTM)
10.44%
3-year revenue growth (CAGR)
9.70%
10-year revenue growth (CAGR)
12.28%
3-year earnings per share growth (CAGR)
14.51%
10-year earnings per share growth (CAGR)
13.98%
3-year dividend per share growth (CAGR)
6.27%
10-year dividend per share growth (CAGR)
7.18%
Bulls say / Bears say
CMC Development sales rose 39.5% in local currencies in the first half, pointing to strong demand for Bachem’s development work and a growing project pipeline. (Bachem)
Bachem says its orders for the rest of 2026 are booked, and Building K has started making commercial products. If the new facility ramps as planned, it could support the company’s 35–40% local-currency sales growth forecast for 2026. (Bachem, EarningsCalls.dev)
A large-volume peptide supply agreement includes pre-payments and long-term commitments, giving Bachem added demand visibility for its planned Sisslerfeld site and beyond 2030. (Bachem)
First-half EBITDA fell 9% and the EBITDA margin dropped to 25.4% from 29.1%, showing that expansion and ramp-up costs are already weighing on profitability. (Bachem)
The 2026 sales growth forecast was narrowed from 35–45% to 35–40%, while Commercial API sales fell 19.3% in local currencies in the first half. That leaves a demanding second-half delivery task, with growth hinging on the recovery management expects. (Bachem)
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2026.
Upcoming events
No upcoming events
Funds containing BANB
AllUSDEURGBP
Fund name | Fund size | Fr. BANB weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.30% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.30% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.30% |
Xtrackers MSCI Europe Small Cap£XXSC | $3.6B | 0.20% |
Xtrackers MSCI Europe Small Cap€DX2J | $3.6B | 0.20% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.